Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XORTX Therapeutics Inc. filings document foreign issuer reports for a clinical-stage pharmaceutical company developing therapies for gout and progressive kidney disease. The records describe its XRx-026, XRx-008, XRx-101, XRx-225 and VB4-P5 programs, including disease focus, development stage and acquired intellectual property, regulatory documentation and manufacturing data for the VB4-P5 kidney anti-fibrotic asset.
The company’s Form 6-K disclosures also cover capital structure and exchange-listing matters, including a completed share consolidation, Nasdaq continued-listing compliance, preliminary stockholders’ equity information, acquisition consideration involving common shares and pre-funded warrants, and shareholder meeting results. Governance filings report director elections, auditor appointments, stock option plan approval and related voting outcomes.
XORTX Therapeutics Inc. reports that it has regained compliance with Nasdaq’s continued listing rules for the minimum bid price. Nasdaq requires shares to maintain a bid of at least US$1.00 per share for 10 consecutive trading days. After a 1-for-5 reverse split of its common shares on April 6, 2026, this requirement was met on April 17, 2026, and XORTX received a Nasdaq compliance letter on April 20, 2026, curing the prior deficiency.
XORTX Therapeutics has closed the acquisition of Vectus Biosystems’ VB4-P5 kidney anti-fibrotic program for total consideration of US$3.0 million. The deal adds a pre-IND small-molecule candidate targeting kidney fibrosis in both rare and common chronic kidney diseases, an area with significant unmet need.
As payment, XORTX issued 154,544 common shares and 692,150 pre-funded warrants, each warrant exercisable at US$0.0001 and capped so Vectus cannot own more than 9.99% of XORTX’s common shares. The warrants expire on April 13, 2031, and the TSX Venture Exchange has conditionally approved listing all shares issuable under the transaction.
XORTX Therapeutics Inc. filed a Form 6-K confirming the effective details of its previously announced share consolidation. The consolidation will occur on April 6, 2026, on the basis of one new common share for every five old common shares, following approvals from the TSX Venture Exchange and Nasdaq Stock Exchange.
The company is a late-stage clinical pharmaceutical business with three clinically advanced programs targeting gout and progressive kidney diseases, plus an additional pre-clinical program for Type 2 diabetic nephropathy.
XORTX Therapeutics Inc. reported the results of its annual and special shareholder meeting held on March 24, 2026. Shareholders representing 2,407,148 common shares, approximately 35% of the shares outstanding, were present.
All items on the agenda were approved, including the election of five management nominees to the board, re-appointment of Davidson & Company LLP as auditors with directors authorized to set their pay, re-approval of the stock option plan and approval of a share consolidation.
XORTX Therapeutics Inc. reported shareholder voting results from its annual general and special meeting held on March 24, 2026. Shareholders approved setting the board at five directors and elected all nominees with strong support, including several at 100% of votes cast.
They reappointed Davidson & Co. LLP as auditor and re‑approved the stock option plan, which reserves up to 10% of issued and outstanding common shares at the grant date. Shareholders also authorized a share consolidation of up to 5 pre‑consolidation shares for 1 post‑consolidation share to help the company regain compliance with NASDAQ Capital Market continued listing requirements.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.
XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.
XORTX Therapeutics Inc. is carrying out a share consolidation, exchanging one new common share for every five existing shares to help maintain its Nasdaq listing. This 1‑for‑5 consolidation will reduce issued and outstanding shares from 6,962,218 to approximately 1,392,444.
The company will keep its current name, and its stock will continue trading on the TSX Venture Exchange and Nasdaq under the symbol XRTX on a post‑consolidation basis with a new CUSIP. All convertible securities will be proportionately adjusted, and fractional shares will be cancelled or rounded up without any cash payments.
XORTX Therapeutics Inc. reports that shareholders have approved a share consolidation, authorizing the board to combine up to five existing common shares into one new common share. The board may implement this consolidation within one year of the March 24, 2026 meeting, subject to TSX Venture Exchange approval.
The company states the primary purpose is to help maintain compliance with Nasdaq’s continued listing requirements that its shares trade above $1.00, including a condition that they trade above $1.00 for 10 days by April 13, 2026. XORTX currently has 6,962,218 common shares outstanding, which would become approximately 1,392,443 post-consolidation, depending on the treatment of fractional shares. No name change will occur, and fractional holdings will be cancelled or rounded up according to set thresholds.
XORTX Therapeutics Inc., a clinical-stage biotechnology company based in Canada and listed on Nasdaq, filed its annual report for the year ended December 31, 2025. The company focuses on kidney and metabolic diseases using small-molecule drugs.
XORTX reported net losses of US$2,158,065 in 2023, US$3,313,346 in 2024 and US$2,656,304 in 2025, with an accumulated deficit of about US$23,824,557 as of December 31, 2025. It has no approved products and has not generated revenue from product sales.
The lead program, XRx-026 for gout, is the most advanced; XRx-008 for ADPKD holds U.S. Orphan Drug Designation, and XRx-101 targets acute kidney injury linked to respiratory virus infections. Management warns it expects continued losses, needs substantial additional funding, faces significant clinical, regulatory and commercialization risks, and could experience share price volatility with potential dilution for shareholders.
XORTX Therapeutics Inc. has proposed three new director nominees for election at its March 24, 2026 annual and special shareholder meeting. George Scorsis, Richard Grieve and Mika Grasso will stand for election in place of three current nominees.
The change is tied to a significant financing initiative, which requires these new directors to join the board as a condition of closing and remains subject to TSX Venture Exchange approval. If the financing is not completed, the new directors will resign and the resulting vacancies will be filled later by the company.
Management proxies will be voted in favour of the new nominees unless shareholders withhold votes. The board unanimously recommends voting for all resolutions, while XORTX continues advancing late-stage programs targeting gout and progressive kidney disease.